IGF-1 LR3

Compound background

IGF-1 LR3 is a 83-amino-acid analog of insulin-like growth factor 1 engineered by (1) extending the native 70-residue sequence with a 13-residue N-terminal peptide and (2) replacing the third amino acid with arginine. These changes reduce its affinity for IGF-binding proteins and protect it from rapid enzymatic cleavage, prolonging plasma half-life from ~10 min to 6–10 h. Freed from most carrier constraints, IGF-1 LR3 more readily engages IGF-1 receptors (and, to a lesser extent, insulin receptors), triggering the canonical PI3K-Akt-mTOR and MAPK/ERK pathways that drive glucose uptake, protein synthesis, mitosis, and tissue remodeling.

Quality standards

• Greater than 99% pure ✅
• LPS/Endotoxins  ✅
• Heavy metals ✅
• Sterility guaranteed ✅

Sourcing standards

• Raw ingredients manufactured by an FDA registered & audited supplier following cGMP standards
• Finished peptides 0.22 µm sterile-filtered (aseptically processed) and produced in a GMP facility
• Tested by a US FDA registered & audited third-party analytical lab accredited by ISO/IEC and U.S. Department of Ecology